New Pharmaxis Board Appointment

SYDNEY, Australia, June 23 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis
(ASX: PXS; Nasdaq: PXSL) today announced the appointment of senior Australian
pharmaceutical executive Will Delaat to its board of directors.
Mr Delaat has 35 years experience in the global pharmaceutical industry,
most recently as the managing director of the Australian subsidiary of Merck &
Co., a position he held from 1997 until his recent retirement.
During his career Mr Delaat has held executive positions in both Europe
and Australia for Merck and AstraZeneca. Mr Delaat is experienced in sales and
marketing and has been responsible for international product launches and
commercialisation of respiratory products.
Mr Delaat also serves the pharmaceutical industry in important
representative roles. He is chairman of the Australian pharmaceutical
industry's peak body, Medicines Australia, and is chairman of the
Pharmaceuticals Industry Council.
''Will Delaat is one of Australia's pharmaceutical industry leaders'' said
Pharmaxis Chairman, Denis Hanley. ''The Pharmaxis board will benefit from his
invaluable skills and experience.''
In accepting the board director position Mr Delaat said: ''Pharmaxis holds
enormous promise and I look forward to being part of its effort to bring
innovative medicines to patients world-wide."
For information on all Pharmaxis Board members, go to
http://tinyurl.com/3s4g2n .
Forward-Looking Statements
The statements contained in this media release that are not purely
historical are forward-looking statements within the meaning of Section 21E of
the Securities Exchange Act of 1934, as amended. Forward-looking statements in
this media release include statements regarding our expectations, beliefs,
hopes, goals, intentions, initiatives or strategies, including statements
regarding the potential for Aridol and/or Bronchitol. All
forward-looking statements included in this media release are based upon
information
available to us as of the date hereof, and we assume no obligation to update
any such forward-looking statement as a result of new information, future
events or otherwise. We can not guarantee that any product candidate will
receive FDA or other regulatory approval or that we will seek any such
approval. Factors that could cause or contribute to such differences include,
but are not limited to, factors discussed in the "Risk Factors and Other
Uncertainties" section of our Form 20-F lodged with the U.S. Securities and
Exchange Commission.
CONTACT:

Alan Robertson
Chief Executive Officer
Tel: +61-2-9454-7200
Email: alan.robertson@pharmaxis.com.au

RELEASED THROUGH:

Australia:
Virginia Nicholls
Tel: +61-417-610-824
Email: virginia.nicholls@pharmaxis.com.au

United States:
Brandon Lewis, Trout Group
Tel: +1-646-378-2915
Email: blewis@troutgroup.com

SOURCE Pharmaxis Ltd

Alan Robertson, Chief Executive Officer of Pharmaxis, +61-2-9454-7200,
alan.robertson@pharmaxis.com.au